Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC)

BACKGROUND: To compare the efficacy and safety of CAPIRI+bevacizumab (Bev) in comparison with FOLFIRI+Bev as first-line treatment for patients with metastatic colorectal cancer (mCRC). METHODS: Patients were randomised to receive either FOLFIRI plus Bev 5 mg kg(−1) every 2 weeks (Arm-A) or CAPIRI pl...

Descripción completa

Detalles Bibliográficos
Autores principales: Souglakos, J, Ziras, N, Kakolyris, S, Boukovinas, I, Kentepozidis, N, Makrantonakis, P, Xynogalos, S, Christophyllakis, Ch, Kouroussis, Ch, Vamvakas, L, Georgoulias, V, Polyzos, A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Clinical Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3273357/
https://www.ncbi.nlm.nih.gov/pubmed/22240792
http://dx.doi.org/10.1038/bjc.2011.594

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3273357/
https://www.ncbi.nlm.nih.gov/pubmed/22240792
http://dx.doi.org/10.1038/bjc.2011.594

Ejemplares similares